Table 2.
Sex-specific summary statistics with thyroid disease prevalence by weighted (95% CIs) quartile of PFOA and PFOS.
| Summary statistics by quartile |
Thyroid disease ever |
Current thyroid disease with thyroid medication |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | Range (ng/mL) | Mean ± SD (ng/mL) | Weighted mean (95% CI) (ng/mL) | n (case/total) | Prevalence (%) |
n (case/total) | Prevalence (%) |
|||
| Unweighted | Weighted | Unweighted | Weighted | |||||||
| Women | ||||||||||
| PFOA | ||||||||||
| All | 2,066 | 0.1–123.0 | 4.25 ± 4.92 | 4.84 (4.35–5.33) | 292/2,066 | 14.13 | 16.18 (14.44–18.09) | 163/2,066 | 7.89 | 9.89 (8.32–11.72) |
| Q1 | 689 | 0.1–2.6 | 1.71 ± 0.66 | 1.79 (1.72–1.85) | 65/689 | 9.43 | 12.62 (9.66–15.57) | 34/689 | 4.93 | 8.14 (5.75–10.53) |
| Q2 | 550 | 2.7–4.0 | 3.32 ± 0.40 | 3.33 (3.28–3.38) | 71/550 | 12.91 | 13.87 (9.66–18.08) | 35/550 | 6.36 | 7.27 (4.37–10.16) |
| Q3 | 441 | 4.1–5.7 | 4.79 ± 0.48 | 4.78 (4.72–4.85) | 72/441 | 16.33 | 15.98 (11.81–20.15) | 39/441 | 8.84 | 8.25 (4.97–11.52) |
| Q4 | 386 | 5.7–123.0 | 9.47 ± 9.38 | 9.7 (8.43–10.98) | 84/386 | 21.76 | 22.57 (17.44–27.71) | 55/386 | 14.25 | 16.18 (11.74–20.62) |
| PFOS | ||||||||||
| All | 2,066 | 0.14–406.0 | 23.24 ± 23.13 | 24.78 (22.6–26.9) | 292/2,066 | 14.13 | 16.18 (14.44–18.09) | 163/2,066 | 7.89 | 9.89 (8.32–11.72) |
| Q1 | 616 | 0.14–12.4 | 8.13 ± 2.82 | 8.49 (8.06–8.93) | 68/616 | 11.04 | 15.14 (10.82–19.46) | 32/616 | 5.19 | 8.7 (5.45–11.96) |
| Q2 | 523 | 12.5–19.4 | 15.75 ± 2.02 | 15.92 (15.71–16.13) | 71/523 | 13.58 | 16.23 (12.58–19.89) | 40/523 | 7.65 | 9.85 (6.58–13.13) |
| Q3 | 466 | 19.5–29.8 | 24.21 ± 2.89 | 24.49 (24.03–24.94) | 62/466 | 13.30 | 12.69 (8.59–16.78) | 39/466 | 8.37 | 8.47 (4.98–11.97) |
| Q4 | 461 | 29.9–406.0 | 50.96 ± 35.15 | 50.48 (45.81–55.16) | 91/461 | 19.74 | 20.66 (16.46–24.87) | 52/461 | 11.28 | 12.55 (8.86–16.23) |
| Men | ||||||||||
| PFOA | ||||||||||
| All | 1,900 | 0.1–45.9 | 5.23 ± 3.41 | 5.79 (5.41–6.18) | 69/1,900 | 3.63 | 3.06 (2.40–3.88) | 46/1,900 | 2.42 | 1.88 (1.30–2.69) |
| Q1 | 643 | 0.1–3.6 | 2.47 ± 0.85 | 2.51 (2.43–2.58) | 24/643 | 3.73 | 3.49 (2.01–4.97) | 16/643 | 2.49 | 2.27 (1.25–3.30) |
| Q2 | 517 | 3.7–5.2 | 4.42 ± 0.45 | 4.44 (4.39–4.50) | 20/517 | 3.87 | 3.44 (1.48–5.41) | 13/517 | 2.51 | 2.14 (0.79–3.49) |
| Q3 | 381 | 5.3–7.2 | 6.12 ± 0.55 | 6.19 (6.12–6.26) | 11/381 | 2.89 | 1.51 (0.38–2.63) | 7/381 | 1.84 | 0.77 (0.17–1.37) |
| Q4 | 359 | 7.3–45.9 | 10.39 ± 4.20 | 10.3 (9.72–10.89) | 14/359 | 3.90 | 3.71 (1.67–5.75) | 10/359 | 2.79 | 2.27 (0.22–4.33) |
| PFOS | ||||||||||
| All | 1,900 | 0.3–435.0 | 29.57 ± 22.11 | 30.36 (28.2–32.5) | 69/1,900 | 3.63 | 3.06 (2.40–3.88) | 46/1,900 | 2.42 | 1.88 (1.30–2.69) |
| Q1 | 529 | 0.3–18.0 | 12.29 ± 4.30 | 12.35 (11.94–12.76) | 18/529 | 3.40 | 3.22 (1.86–4.57) | 10/529 | 1.89 | 1.85 (0.82–2.89) |
| Q2 | 480 | 18.2–25.5 | 21.82 ± 2.13 | 21.83 (21.63–22.03) | 13/480 | 2.71 | 1.64 (0.40–2.87) | 8/480 | 1.67 | 0.80 (0.12–1.48) |
| Q3 | 454 | 25.6–36.7 | 30.81 ± 3.18 | 30.93 (30.57–31.29) | 15/454 | 3.30 | 2.68 (1.26–4.10) | 11/454 | 2.42 | 1.62 (0.55–2.69) |
| Q4 | 437 | 36.8–435.0 | 57.73 ± 29.4 | 56.45 (52.85–60.04) | 23/437 | 5.26 | 4.69 (2.44–6.95) | 17/437 | 3.89 | 3.24 (1.07–5.40) |
Quartiles (Q1–Q4) reflect the U.S. population, accounting for population weighting in NHANES.